Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases
•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetra...
Gespeichert in:
Veröffentlicht in: | Biochemical and biophysical research communications 2014-03, Vol.445 (2), p.451-456 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 456 |
---|---|
container_issue | 2 |
container_start_page | 451 |
container_title | Biochemical and biophysical research communications |
container_volume | 445 |
creator | Schreuder, Herman A. Liesum, Alexander Kroll, Katja Böhnisch, Britta Buning, Christian Ruf, Sven Sadowski, Thorsten |
description | •The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound.
The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme. |
doi_str_mv | 10.1016/j.bbrc.2014.02.014 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22416308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X14002666</els_id><sourcerecordid>1508414650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</originalsourceid><addsrcrecordid>eNp9kE1v1DAURS0EokPhD7BAltiwIOl7jpOZSGyqUQtIldh00Q2y_PFMPcrEg-2M1H9PohSWrO7inXv1dBh7j1AjYHd1qI1JthaAsgZRz_GCbRB6qASCfMk2ANBVoseHC_Ym5wMAouz61-xCyLaBHuWG_dynp1z0wHNJky1TIh49t7o80imHkV9_5pqP8UwDLzr9osJ9THy-8pJIlyONZS0kF-JZZzsNOnEXMulM-S175fWQ6d1zXrL725v7_bfq7sfX7_vru8o2O1kqch22jTZk_Na3vm-xE8126wCpp07s0GoSBrvWutZvnXS-Ma7pvZHSoBHNJfu4zsZcgso2FLKPNo4j2aKEkNg1sJupTyt1SvH3RLmoY8iWhkGPFKessIWdnAW1MKNiRW2KOSfy6pTCUacnhaAW9-qgFvdqca9AqDnm0ofn_ckcyf2r_JU9A19WgGYV50BpeZVGSy6k5VMXw__2_wDys5W2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1508414650</pqid></control><display><type>article</type><title>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Schreuder, Herman A. ; Liesum, Alexander ; Kroll, Katja ; Böhnisch, Britta ; Buning, Christian ; Ruf, Sven ; Sadowski, Thorsten</creator><creatorcontrib>Schreuder, Herman A. ; Liesum, Alexander ; Kroll, Katja ; Böhnisch, Britta ; Buning, Christian ; Ruf, Sven ; Sadowski, Thorsten</creatorcontrib><description>•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound.
The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2014.02.014</identifier><identifier>PMID: 24530914</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; BRADYKININ ; CARBOXYPEPTIDASES ; CARDIOVASCULAR DISEASES ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - enzymology ; Cathepsin A - antagonists & inhibitors ; Cathepsin A - chemistry ; Cathepsin A - isolation & purification ; Cathepsin A - metabolism ; CATHEPSINS ; CHEMICAL BONDS ; COVALENCE ; Covalent inhibitor ; CRYSTAL STRUCTURE ; Crystallography, X-Ray ; DISULFIDES ; Drug Discovery ; DRUGS ; Endothelin ; HEART FAILURE ; Humans ; HYPERTROPHY ; Ligands ; Models, Molecular ; Molecular Targeted Therapy ; PEPTIDE HORMONES ; PH VALUE ; Protein Binding ; Protein Conformation ; Recombinant Proteins - chemistry ; Recombinant Proteins - isolation & purification ; Recombinant Proteins - metabolism ; SERINE ; Serine carboxypeptidase ; Tetrahedral intermediate</subject><ispartof>Biochemical and biophysical research communications, 2014-03, Vol.445 (2), p.451-456</ispartof><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</citedby><cites>FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006291X14002666$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24530914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22416308$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Schreuder, Herman A.</creatorcontrib><creatorcontrib>Liesum, Alexander</creatorcontrib><creatorcontrib>Kroll, Katja</creatorcontrib><creatorcontrib>Böhnisch, Britta</creatorcontrib><creatorcontrib>Buning, Christian</creatorcontrib><creatorcontrib>Ruf, Sven</creatorcontrib><creatorcontrib>Sadowski, Thorsten</creatorcontrib><title>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound.
The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>BRADYKININ</subject><subject>CARBOXYPEPTIDASES</subject><subject>CARDIOVASCULAR DISEASES</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - enzymology</subject><subject>Cathepsin A - antagonists & inhibitors</subject><subject>Cathepsin A - chemistry</subject><subject>Cathepsin A - isolation & purification</subject><subject>Cathepsin A - metabolism</subject><subject>CATHEPSINS</subject><subject>CHEMICAL BONDS</subject><subject>COVALENCE</subject><subject>Covalent inhibitor</subject><subject>CRYSTAL STRUCTURE</subject><subject>Crystallography, X-Ray</subject><subject>DISULFIDES</subject><subject>Drug Discovery</subject><subject>DRUGS</subject><subject>Endothelin</subject><subject>HEART FAILURE</subject><subject>Humans</subject><subject>HYPERTROPHY</subject><subject>Ligands</subject><subject>Models, Molecular</subject><subject>Molecular Targeted Therapy</subject><subject>PEPTIDE HORMONES</subject><subject>PH VALUE</subject><subject>Protein Binding</subject><subject>Protein Conformation</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - isolation & purification</subject><subject>Recombinant Proteins - metabolism</subject><subject>SERINE</subject><subject>Serine carboxypeptidase</subject><subject>Tetrahedral intermediate</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAURS0EokPhD7BAltiwIOl7jpOZSGyqUQtIldh00Q2y_PFMPcrEg-2M1H9PohSWrO7inXv1dBh7j1AjYHd1qI1JthaAsgZRz_GCbRB6qASCfMk2ANBVoseHC_Ym5wMAouz61-xCyLaBHuWG_dynp1z0wHNJky1TIh49t7o80imHkV9_5pqP8UwDLzr9osJ9THy-8pJIlyONZS0kF-JZZzsNOnEXMulM-S175fWQ6d1zXrL725v7_bfq7sfX7_vru8o2O1kqch22jTZk_Na3vm-xE8126wCpp07s0GoSBrvWutZvnXS-Ma7pvZHSoBHNJfu4zsZcgso2FLKPNo4j2aKEkNg1sJupTyt1SvH3RLmoY8iWhkGPFKessIWdnAW1MKNiRW2KOSfy6pTCUacnhaAW9-qgFvdqca9AqDnm0ofn_ckcyf2r_JU9A19WgGYV50BpeZVGSy6k5VMXw__2_wDys5W2</recordid><startdate>20140307</startdate><enddate>20140307</enddate><creator>Schreuder, Herman A.</creator><creator>Liesum, Alexander</creator><creator>Kroll, Katja</creator><creator>Böhnisch, Britta</creator><creator>Buning, Christian</creator><creator>Ruf, Sven</creator><creator>Sadowski, Thorsten</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20140307</creationdate><title>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</title><author>Schreuder, Herman A. ; Liesum, Alexander ; Kroll, Katja ; Böhnisch, Britta ; Buning, Christian ; Ruf, Sven ; Sadowski, Thorsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-ed6153abebf7f5f95162377d01e9e6281cae2b165cd5f7d4df3bd39fb44b1b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>BRADYKININ</topic><topic>CARBOXYPEPTIDASES</topic><topic>CARDIOVASCULAR DISEASES</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - enzymology</topic><topic>Cathepsin A - antagonists & inhibitors</topic><topic>Cathepsin A - chemistry</topic><topic>Cathepsin A - isolation & purification</topic><topic>Cathepsin A - metabolism</topic><topic>CATHEPSINS</topic><topic>CHEMICAL BONDS</topic><topic>COVALENCE</topic><topic>Covalent inhibitor</topic><topic>CRYSTAL STRUCTURE</topic><topic>Crystallography, X-Ray</topic><topic>DISULFIDES</topic><topic>Drug Discovery</topic><topic>DRUGS</topic><topic>Endothelin</topic><topic>HEART FAILURE</topic><topic>Humans</topic><topic>HYPERTROPHY</topic><topic>Ligands</topic><topic>Models, Molecular</topic><topic>Molecular Targeted Therapy</topic><topic>PEPTIDE HORMONES</topic><topic>PH VALUE</topic><topic>Protein Binding</topic><topic>Protein Conformation</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - isolation & purification</topic><topic>Recombinant Proteins - metabolism</topic><topic>SERINE</topic><topic>Serine carboxypeptidase</topic><topic>Tetrahedral intermediate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schreuder, Herman A.</creatorcontrib><creatorcontrib>Liesum, Alexander</creatorcontrib><creatorcontrib>Kroll, Katja</creatorcontrib><creatorcontrib>Böhnisch, Britta</creatorcontrib><creatorcontrib>Buning, Christian</creatorcontrib><creatorcontrib>Ruf, Sven</creatorcontrib><creatorcontrib>Sadowski, Thorsten</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schreuder, Herman A.</au><au>Liesum, Alexander</au><au>Kroll, Katja</au><au>Böhnisch, Britta</au><au>Buning, Christian</au><au>Ruf, Sven</au><au>Sadowski, Thorsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2014-03-07</date><risdate>2014</risdate><volume>445</volume><issue>2</issue><spage>451</spage><epage>456</epage><pages>451-456</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>•The structures of active cathepsin A and the inactive precursor are very similar.•The only major difference is the absence of a 40 residue activation domain.•The termini of the active catalytic core are held together by a disulfide bond.•Compound 1 reacts with the catalytic Ser150, building a tetrahedral intermediate.•Compound 2 is cleaved by the enzyme and a fragment remained bound.
The lysosomal serine carboxypeptidase cathepsin A is involved in the breakdown of peptide hormones like endothelin and bradykinin. Recent pharmacological studies with cathepsin A inhibitors in rodents showed a remarkable reduction in cardiac hypertrophy and atrial fibrillation, making cathepsin A a promising target for the treatment of heart failure. Here we describe the crystal structures of activated cathepsin A without inhibitor and with two compounds that mimic the tetrahedral intermediate and the reaction product, respectively. The structure of activated cathepsin A turned out to be very similar to the structure of the inactive precursor. The only difference was the removal of a 40 residue activation domain, partially due to proteolytic removal of the activation peptide, and partially by an order–disorder transition of the peptides flanking the removed activation peptide. The termini of the catalytic core are held together by the Cys253–Cys303 disulfide bond, just before and after the activation domain. One of the compounds we soaked in our crystals reacted covalently with the catalytic Ser150 and formed a tetrahedral intermediate. The other compound got cleaved by the enzyme and a fragment, resembling one of the natural reaction products, was found in the active site. These studies establish cathepsin A as a classical serine proteinase with a well-defined oxyanion hole. The carboxylate group of the cleavage product is bound by a hydrogen-bonding network involving one aspartate and two glutamate side chains. This network can only form if at least half of the carboxylate groups involved are protonated, which explains the acidic pH optimum of the enzyme.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24530914</pmid><doi>10.1016/j.bbrc.2014.02.014</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-291X |
ispartof | Biochemical and biophysical research communications, 2014-03, Vol.445 (2), p.451-456 |
issn | 0006-291X 1090-2104 |
language | eng |
recordid | cdi_osti_scitechconnect_22416308 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | 60 APPLIED LIFE SCIENCES BRADYKININ CARBOXYPEPTIDASES CARDIOVASCULAR DISEASES Cardiovascular Diseases - drug therapy Cardiovascular Diseases - enzymology Cathepsin A - antagonists & inhibitors Cathepsin A - chemistry Cathepsin A - isolation & purification Cathepsin A - metabolism CATHEPSINS CHEMICAL BONDS COVALENCE Covalent inhibitor CRYSTAL STRUCTURE Crystallography, X-Ray DISULFIDES Drug Discovery DRUGS Endothelin HEART FAILURE Humans HYPERTROPHY Ligands Models, Molecular Molecular Targeted Therapy PEPTIDE HORMONES PH VALUE Protein Binding Protein Conformation Recombinant Proteins - chemistry Recombinant Proteins - isolation & purification Recombinant Proteins - metabolism SERINE Serine carboxypeptidase Tetrahedral intermediate |
title | Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A58%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crystal%20structure%20of%20cathepsin%20A,%20a%20novel%20target%20for%20the%20treatment%20of%20cardiovascular%20diseases&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Schreuder,%20Herman%20A.&rft.date=2014-03-07&rft.volume=445&rft.issue=2&rft.spage=451&rft.epage=456&rft.pages=451-456&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2014.02.014&rft_dat=%3Cproquest_osti_%3E1508414650%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1508414650&rft_id=info:pmid/24530914&rft_els_id=S0006291X14002666&rfr_iscdi=true |